In particular, clinically viable selective KOR antagonists have been highly anticipated due to wide consensus in the preclinical literature that systemic blockade of KORs holds great promise for the treatment of several neuropsychiatric disorders including depression, substance use disorders, and anxiety [9–12]. This evidence concerns the gene OPRK1 and major depressive disorder.